comparemela.com

Latest Breaking News On - Dane leone - Page 6 : comparemela.com

Seagen, Astellas win expanded FDA approval for bladder cancer drug

BioPharma

United statesAstellas pharmaRaymond jamesAhsan arozullahDane leoneDrug administrationMerck co

StockWatch: COPD Data, Analysts, Treg Cell Therapy Deal Lift Regeneron

Regeneron Pharmaceuticals shares rose 10% following positive Phase III data for Dupixent® in chronic obstructive pulmonary disease (COPD).

United statesIsrael generalKiryat gatDane leoneCodiak biosciencesDavid risingerRegeneron velocisuiteBrianp skorneyHans engelDouglase williamsAndrew obenshainCarter gouldMohit bansalAkash tewariChris schottSonoma biotherapeutics

StockWatch: Antitrust Fears Dampen Support for $43B Pfizer-Seagen Deal

Pfizer's planned $43 billion purchase of Seagen didn't spark the usual huge stock surge, due to antitrust review concerns.

David risingerJay olsonGregory renzaRaymond jamesAlbert bourlaZhiqiang shuGena wangEtzer daroutReni benjaminDane leoneAndrew berensDavid epsteinBiotech equity researchMerck coMerck kgaEuropean union

In Pfizer-Seagen review, FTC has chance to set new pharma precedent

BioPharma

Veltrop harkriderRaymond jamesStephen willeyDane leoneDoug lanklerJeny maierLina khanSeagen padcevBristol myersMerck coBristol myers squibbFederal trade commissionChairwoman lina khan

Ocular Therapeutix, Inc (NASDAQ:OCUL) Q4 2022 Earnings Call Transcript

Operator: Good afternoon, ladies and gentlemen. Thank you for standing by and welcome to the Ocular Therapeutix Fourth Quarter and Year-End 2022 Earnings Conference Call.

Steve meyersRaymond jamesJon wollebenChris whiteAntony mattessichRabia ozdenAndrew moshfeghiPeter kaiserDane leoneDonald notmanOcular therapeutix incOcular therapeutixCall transcript marchOcular therapeutix fourth quarterChief financial officerChief executive officer

vimarsana © 2020. All Rights Reserved.